In recent years, much focus has been on developing immune checkpoint inhibitors (ICIs), monoclonal antibodies that target negative regulators of T cell activation, namely CTLA-4 and PD-1 on Treg cells or T cells and PD-L1 on tumor cells 173-176. Here, CTLA4 is linked to neoplasm.